Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib

Over the past two decades, many new variants of targeted therapy for metastatic colorectal cancer (mCRC) had appeared, and significantly increased patient survival. However, there were questions relating to the definition of the optimal sequence and the combination of different drugs. Cytotoxic agen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. I. Sekacheva, R. I. Nuriev, A. A. Rozhkov, A. V. Semenkov, N. N. Bagmet, A. M. Boroda
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	metastatic colorectal cancer targeted therapy of colorectal cancer regorafenib sequential therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5e4f261f79964feabb01d7d3d9dc1d9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e4f261f79964feabb01d7d3d9dc1d9c
record_format	dspace
spelling	oai:doaj.org-article:5e4f261f79964feabb01d7d3d9dc1d9c2021-11-30T17:03:34ZModern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib1815-14341815-144210.26442/18151434.2020.3.200342https://doaj.org/article/5e4f261f79964feabb01d7d3d9dc1d9c2020-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/52593/36039https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Over the past two decades, many new variants of targeted therapy for metastatic colorectal cancer (mCRC) had appeared, and significantly increased patient survival. However, there were questions relating to the definition of the optimal sequence and the combination of different drugs. Cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil and capecitabine, are the basis of the treatment of mCRC. In addition, the arsenal of modern oncologist includes the group of drugs inhibiting the epidermal growth factors (for example, cetuximab and panitumumab) and inhibiting tumor angiogenesis factors (for example, bevacizumab and aflibercept). Moreover, the use of immuno-oncology drugs, trastuzumab or encorafenib is possible in case of knowing tumor-specific molecular signature. Unfortunately, these new indications can be used only in small proportion of patients. The multikinase inhibitor regorafenib takes a special place, it can be used in patients in spite of RAS mutation status. The increasing attention has been paid to the selection of the drugs for sequential therapy of mCRC, recently. This review discusses important clinical data on the direct role of targeted drugs in the treatment of mCRC in different subgroups of patients.M. I. SekachevaR. I. NurievA. A. RozhkovA. V. SemenkovN. N. BagmetA. M. BorodaIP Habib O.N.articlemetastatic colorectal cancertargeted therapy of colorectal cancerregorafenibsequential therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 3, Pp 109-113 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	metastatic colorectal cancer targeted therapy of colorectal cancer regorafenib sequential therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	metastatic colorectal cancer targeted therapy of colorectal cancer regorafenib sequential therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 M. I. Sekacheva R. I. Nuriev A. A. Rozhkov A. V. Semenkov N. N. Bagmet A. M. Boroda Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
description	Over the past two decades, many new variants of targeted therapy for metastatic colorectal cancer (mCRC) had appeared, and significantly increased patient survival. However, there were questions relating to the definition of the optimal sequence and the combination of different drugs. Cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil and capecitabine, are the basis of the treatment of mCRC. In addition, the arsenal of modern oncologist includes the group of drugs inhibiting the epidermal growth factors (for example, cetuximab and panitumumab) and inhibiting tumor angiogenesis factors (for example, bevacizumab and aflibercept). Moreover, the use of immuno-oncology drugs, trastuzumab or encorafenib is possible in case of knowing tumor-specific molecular signature. Unfortunately, these new indications can be used only in small proportion of patients. The multikinase inhibitor regorafenib takes a special place, it can be used in patients in spite of RAS mutation status. The increasing attention has been paid to the selection of the drugs for sequential therapy of mCRC, recently. This review discusses important clinical data on the direct role of targeted drugs in the treatment of mCRC in different subgroups of patients.
format	article
author	M. I. Sekacheva R. I. Nuriev A. A. Rozhkov A. V. Semenkov N. N. Bagmet A. M. Boroda
author_facet	M. I. Sekacheva R. I. Nuriev A. A. Rozhkov A. V. Semenkov N. N. Bagmet A. M. Boroda
author_sort	M. I. Sekacheva
title	Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
title_short	Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
title_full	Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
title_fullStr	Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
title_full_unstemmed	Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
title_sort	modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/5e4f261f79964feabb01d7d3d9dc1d9c
work_keys_str_mv	AT misekacheva modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib AT rinuriev modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib AT aarozhkov modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib AT avsemenkov modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib AT nnbagmet modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib AT amboroda modernperspectivesinsequentialtherapyformetastaticcolorectalcancerwithreferencetotheuseofregorafenib
_version_	1718406381780860928

Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib

Ejemplares similares